Mercer Global Advisors’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $22.1M | Buy |
104,301
+2,455
| +2% | +$482K | 0.03% | 324 |
|
|
2026
Q1 | $20M | Buy |
101,846
+4,219
| +4% | +$820K | 0.03% | 319 |
|
|
2025
Q4 | $16.9M | Buy |
97,627
+4,805
| +5% | +$875K | 0.03% | 369 |
|
|
2025
Q3 | $17.7M | Buy |
92,822
+8,217
| +10% | +$1.46M | 0.03% | 342 |
|
|
2025
Q2 | $15.2M | Buy |
84,605
+10,591
| +14% | +$1.84M | 0.03% | 306 |
|
|
2025
Q1 | $12.5M | Buy |
74,014
+4,862
| +7% | +$799K | 0.03% | 311 |
|
|
2024
Q4 | $10.4M | Sell |
69,152
-7,034
| -9% | -$1.09M | 0.03% | 350 |
|
|
2024
Q3 | $11.7M | Buy |
76,186
+25,363
| +50% | +$3.79M | 0.03% | 294 |
|
|
2024
Q2 | $7.03M | Buy |
50,823
+598
| +1% | +$81.9K | 0.02% | 376 |
|
|
2024
Q1 | $6.68M | Sell |
50,225
-16,136
| -24% | -$2.09M | 0.02% | 391 |
|
|
2023
Q4 | $9.15M | Sell |
66,361
-941
| -1% | -$124K | 0.03% | 324 |
|
|
2023
Q3 | $8.2M | Buy |
67,302
+1,083
| +2% | +$144K | 0.03% | 316 |
|
|
2023
Q2 | $9.31M | Sell |
66,219
-3,863
| -6% | -$533K | 0.04% | 311 |
|
|
2023
Q1 | $9.91M | Sell |
70,082
-2,966
| -4% | -$424K | 0.05% | 274 |
|
|
2022
Q4 | $11.4M | Buy |
73,048
+15,784
| +28% | +$2.27M | 0.06% | 245 |
|
|
2022
Q3 | $7.03M | Buy |
57,264
+1,521
| +3% | +$200K | 0.04% | 299 |
|
|
2022
Q2 | $7.41M | Buy |
55,743
+3,463
| +7% | +$472K | 0.05% | 276 |
|
|
2022
Q1 | $7.16M | Buy |
52,280
+2,065
| +4% | +$288K | 0.04% | 294 |
|
|
2021
Q4 | $8.69M | Buy |
50,215
+981
| +2% | +$149K | 0.05% | 256 |
|
|
2021
Q3 | $7.15M | Buy |
49,234
+1,878
| +4% | +$275K | 0.05% | 280 |
|
|
2021
Q2 | $6.25M | Buy |
47,356
+2,008
| +4% | +$263K | 0.05% | 284 |
|
|
2021
Q1 | $5.82M | Buy |
45,348
+18,246
| +67% | +$2.25M | 0.05% | 270 |
|
|
2020
Q4 | $3.23M | Buy |
27,102
+3,722
| +16% | +$454K | 0.04% | 306 |
|
|
2020
Q3 | $2.68M | Buy |
23,380
+921
| +4% | +$109K | 0.04% | 311 |
|
|
2020
Q2 | $2.56M | Sell |
22,459
-4,130
| -16% | -$438K | 0.05% | 280 |
|
|
2020
Q1 | $2.13M | Buy |
26,589
+6,776
| +34% | +$702K | 0.05% | 311 |
|
|
2019
Q4 | $2.12M | Buy |
19,813
+128
| +0.7% | +$13.3K | 0.04% | 328 |
|
|
2019
Q3 | $2.11M | Buy |
19,685
+796
| +4% | +$81.7K | 0.05% | 296 |
|
|
2019
Q2 | $1.92M | Buy |
18,889
+1,671
| +10% | +$161K | 0.05% | 292 |
|
|
2019
Q1 | $1.55M | Buy |
+17,218
| New | +$1.49M | 0.06% | 296 |
|
Other funds holding DGX
EIG
Mercer Global Advisors's DGX Position: Q2 2026 in Review
Mercer Global Advisors increased its Quest Diagnostics (DGX) stake by 2.4% in Q2 2026, buying an estimated $482K and bringing the position to 104,301 shares worth $22.1M. The position accounts for 0.03% of the portfolio, ranked #324.
Mercer Global Advisors first reported a position in DGX in Q1 2019 and has held it in 30 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Mercer Global Advisors held 104,301 shares of Quest Diagnostics worth $22.1M as of Q2 2026.
- Mercer Global Advisors bought 2,455 Quest Diagnostics shares in Q2 2026, an estimated $482K.
- Quest Diagnostics made up 0.03% of Mercer Global Advisors's portfolio in Q2 2026, its #324 holding.
- Mercer Global Advisors first reported a position in Quest Diagnostics in Q1 2019 and has held it in 30 quarters since.
- 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.